All the Drug Class Drugs
Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 1.34 mg/ml. PREF. PEN: 1×1.5, 3 ml, 3×1.5, 3 ml. Init. dose is 0.25 mg once wkly. After 4 wks. the dose should be incr. to 0.5 mg once wkly. After at least 4 wks. with a dose of 0.5 mg once wkly., the dose can be incr. to 1 mg once wkly. to further improve glycaemic control. Semaglutide 0.25 mg is not a mainten.dose. Wkly. doses higher than 1 mg are not recomm.
When Ozempic is added to existing metformin and/or thiazolidinedione ther., the current dose of metformin and/or thiazolidinedione can be cont. unchanged.
When Ozempic is added to existing ther. of sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be consid. to reduce the risk of hypoglyc. Self-monitor. of blood glucose is not need. in order to adjust the dose of Ozempic.
Miss. dose should be admin.as soon as possible and within 5 d. after the miss. dose. If more than 5 d. have pass., the miss. dose should be skipped, and the next dose should be admin. on the regularly scheduled day. In each case, pts. can then resume their regular once wkly. dosing schedule. See lit.
Tmt. of adults with insuffic. control. type 2 diabet. mell. as an adjunct to diet and exercise. As monother. when metformin is consid. inappropr. due to intoler. or contraindications. In addition to other medicinal products for the tmt. of diabetes.
For study results with respect to combinat., effects on glycaemic control and cardiovasc. events, and the populations studied.
C/I: Hypersens.
Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 3,7,14 mg. Tabs. 30X 3,7 or 14 mg. Start. dose is 3 mg once dly. for one month. After that, dose should be incr. to a maint. dose of 7 mg dly. After at least one month with a dose of 7 mg dly, dose can be incr. to a maint. dose of 14 mg dly. to further improve glyc. contr..
The max. recomm. single daily dose of semaglutide is 14 mg.
Tmt. of adults with insuff. contr. type 2 diabetes mell. to improve glyc. contr. as an adjunct to diet and exercise• as monother. when metformin is inappr. due to intol. or contraindic.• in comb. with other medicine for the tmt. of diabetes.
C/I:Hypersens.
Glucagon-like peptide-1 (GLP-1) analogues. Semaglutide 0.25 mg, 0.5 mg , 1 mg, 1.7 mg, 2.4 mg. Pre-filled pen SC inj. 4X 0.25/0.5/1/1.7/2.4 mg
Adlts and adolesc: maint. dose of 2.4 mg once/w is reached by starting with a dose of 0.25 mg. To reduce likelihood of GI sympt., dose should be escalated over 16-week to the maint. dose of 2.4 mg once/w. See lit.
Adlts: as an adjunct to a red. calorie diet and incr. physical activity for weight managem., includ. weight loss and weight mainten., in adlts. with an initial BMI of
• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in presence of at least one weight-relat. comorbidity e.g. dysglycaemia (prediabetes or type 2 DM), hypertension, dyslipidaemia, obstructive sleep apnoea or CV dis.
Adolesc. (≥12 years): as an adjunct to a red. calorie diet and incr. physical activity for weight managem. in adolesc. with
• obesity* and
• body weight above 60 kg.
Tmt. to be discont. and re-eval. if adolesc. pts. have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or max. toler. dose. *Obesity (BMI ≥95th percentile) as def. on sex- and age-spec. BMI growth charts.
C/I: Hypersens
